[{"address1": "3115 Merryfield Row", "address2": "Suite 300", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 465 6511", "website": "https://www.erasca.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.", "fullTimeEmployees": 126, "companyOfficers": [{"maxAge": 1, "name": "Dr. Jonathan E. Lim M.D.", "age": 51, "title": "Co-Founder, Chairman & CEO", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 987696, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David M. Chacko M.D.", "age": 39, "title": "CFO & Chief Business Officer", "yearBorn": 1984, "fiscalYear": 2023, "totalPay": 666090, "exercisedValue": 0, "unexercisedValue": 948786}, {"maxAge": 1, "name": "Mr. Ebun S. Garner Esq., J.D.", "age": 51, "title": "General Counsel & Corporate Secretary", "yearBorn": 1972, "fiscalYear": 2023, "totalPay": 607440, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael D. Varney Ph.D.", "age": 65, "title": "Chairman of Research & Development, Scientific Advisory Board Member and Director", "yearBorn": 1958, "fiscalYear": 2023, "totalPay": 86503, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Nik  Chetwyn Ph.D.", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Lisa  Tesvich-Bonora Ph.D.", "title": "Chief People Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian L. Baker CPA, M.S.", "age": 56, "title": "Senior Vice President of Finance", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Chandra D. Lovejoy M.S.", "age": 52, "title": "Chief Regulatory Affairs Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Shoemaker Ph.D.", "age": 42, "title": "Senior Vice President of Research", "yearBorn": 1981, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Shannon R. Morris M.D., Ph.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1970, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 3, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.79, "open": 2.79, "dayLow": 2.75, "dayHigh": 3.03, "regularMarketPreviousClose": 2.79, "regularMarketOpen": 2.79, "regularMarketDayLow": 2.75, "regularMarketDayHigh": 3.03, "beta": 1.166, "forwardPE": -3.9342105, "volume": 3573945, "regularMarketVolume": 3573945, "averageVolume": 2006411, "averageVolume10days": 1541340, "averageDailyVolume10Day": 1541340, "bid": 2.96, "ask": 2.99, "bidSize": 800, "askSize": 400, "marketCap": 844686976, "fiftyTwoWeekLow": 1.51, "fiftyTwoWeekHigh": 3.45, "fiftyDayAverage": 2.7528, "twoHundredDayAverage": 2.231725, "currency": "USD", "enterpriseValue": 433397184, "floatShares": 203635771, "sharesOutstanding": 282504000, "sharesShort": 23416352, "sharesShortPriorMonth": 21812070, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0829, "heldPercentInsiders": 0.12397, "heldPercentInstitutions": 0.76874, "shortRatio": 12.72, "shortPercentOfFloat": 0.0942, "bookValue": 1.652, "priceToBook": 1.8099275, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -158280000, "trailingEps": -0.93, "forwardEps": -0.76, "pegRatio": 0.8, "enterpriseToEbitda": -3.011, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "ERAS", "underlyingSymbol": "ERAS", "shortName": "Erasca, Inc.", "longName": "Erasca, Inc.", "firstTradeDateEpochUtc": 1626442200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3eb26e05-0e9c-3836-891c-6af153666702", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.99, "targetHighPrice": 7.0, "targetLowPrice": 3.0, "targetMeanPrice": 4.57, "targetMedianPrice": 4.0, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 408412000, "totalCashPerShare": 1.446, "ebitda": -143948992, "totalDebt": 53968000, "quickRatio": 16.495, "currentRatio": 16.792, "debtToEquity": 11.964, "returnOnAssets": -0.19138001, "returnOnEquity": -0.38898998, "freeCashflow": -86939872, "operatingCashflow": -111342000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]